Incyte cancer drug, Keytruda combo fails late trial

Apr 06, 2018

Incyte and Merck & Co. have halted a phase 3 study evaluating Incyte's epacadostat with Merck's Keytruda in patients with metastatic melanoma after determining that the study did not improve progression-free survival.

Incyte's epacadostat blocks an enzyme called IDO1 and is seen as complementary to the checkpoint inhibitors, such as Keytruda, that have pushed immuno-oncology forward.

The failure of this study is a major blow in the quest to find new types of drugs with the potential to work in combination with checkpoint inhibitors. Success had the potential to be practice-changing in the frontline setting of advanced melanoma.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments